X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (785) 785
immunotherapy (696) 696
oncology (679) 679
anti-pd-1 (677) 677
humans (578) 578
nivolumab (459) 459
melanoma (422) 422
cancer (417) 417
ipilimumab (364) 364
anti-pd-1 antibody (363) 363
safety (334) 334
pembrolizumab (307) 307
immunology (268) 268
female (229) 229
pd-1 (215) 215
metastatic melanoma (211) 211
care and treatment (207) 207
chemotherapy (204) 204
male (194) 194
metastasis (192) 192
tumors (190) 190
blockade (186) 186
middle aged (179) 179
aged (169) 169
open-label (169) 169
programmed cell death 1 receptor - antagonists & inhibitors (164) 164
apoptosis (162) 162
therapy (155) 155
animals (153) 153
patients (153) 153
antibodies, monoclonal - therapeutic use (148) 148
survival (144) 144
lymphocytes (143) 143
cancer therapies (142) 142
expression (136) 136
pd-l1 (136) 136
melanoma - drug therapy (133) 133
antineoplastic agents - therapeutic use (128) 128
advanced melanoma (127) 127
immune checkpoint (127) 127
pd-1 blockade (127) 127
clinical trials (124) 124
research (124) 124
anti-pd-1 therapy (122) 122
antibody (121) 121
adult (119) 119
analysis (119) 119
lung cancer (119) 119
programmed cell death 1 receptor - immunology (116) 116
immunotherapy - methods (111) 111
cell lung-cancer (109) 109
t cells (108) 108
t-cells (106) 106
treatment outcome (106) 106
pd-1 protein (105) 105
review (104) 104
immune checkpoint inhibitors (103) 103
article (101) 101
anti-ctla-4 (100) 100
antibodies, monoclonal - adverse effects (100) 100
medicine, research & experimental (100) 100
antibodies (95) 95
docetaxel (95) 95
cell death (93) 93
antineoplastic agents - adverse effects (88) 88
health aspects (88) 88
aged, 80 and over (86) 86
drug therapy (86) 86
adverse events (85) 85
antigens (84) 84
neoplasms. tumors. oncology. including cancer and carcinogens (84) 84
b7-h1 antigen - antagonists & inhibitors (79) 79
ligands (78) 78
prognosis (78) 78
lymphocytes t (77) 77
pharmacology & pharmacy (76) 76
melanoma - pathology (75) 75
cell biology (74) 74
neoplasms - immunology (74) 74
antibodies, monoclonal, humanized - therapeutic use (73) 73
usage (73) 73
mice (72) 72
immune system (71) 71
medical prognosis (71) 71
lung cancer, non-small cell (70) 70
immune response (69) 69
skin neoplasms - drug therapy (69) 69
medicine & public health (68) 68
cytotoxicity (67) 67
responses (67) 67
toxicity (67) 67
neoplasms - drug therapy (66) 66
immune checkpoint blockade (65) 65
pd-l1 protein (65) 65
tumor-infiltrating lymphocytes (65) 65
biomarkers (64) 64
antibodies, monoclonal, humanized - adverse effects (63) 63
ctla-4 (63) 63
dermatology (63) 63
lung neoplasms - drug therapy (62) 62
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1279) 1279
French (27) 27
German (13) 13
Korean (4) 4
Russian (2) 2
Slovenian (2) 2
Polish (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European Journal of Cancer, ISSN 0959-8049, 12/2017, Volume 87, pp. 216 - 218
Journal Article
European Journal of Cancer, ISSN 0959-8049, 05/2018, Volume 95, pp. 130 - 132
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 10/2018, Volume 24, Issue 20, pp. 4960 - 4967
Purpose: The purpose of this study was to assess the association of baseline tumor size (BTS) with other baseline clinical factors and outcomes in... 
VERSION | THERAPY | ANTI-PD-1 | ONCOLOGY | IPILIMUMAB
Journal Article
International Journal of Dermatology, ISSN 0011-9059, 06/2019, Volume 58, Issue 6, pp. 736 - 738
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 397 - 404
Abstract Background Treatment options for previously treated metastatic triple-negative breast cancer (mTNBC) are limited. In cohort A of the phase II... 
pembrolizumab | triple-negative breast neoplasms | anti-PD-1 | immunotherapy | ONCOLOGY | PD-L1 EXPRESSION | ANTIBODY
Journal Article
British Journal of Dermatology, ISSN 0007-0963, 10/2018, Volume 179, Issue 4, pp. 993 - 994
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 09/2018, Volume 24, Issue 17, pp. 4059 - 4061
Patients with glioblastoma (GBM) exhibit a complex state of immune dysfunction involving multiple mechanisms of local, regional, and systemic immunosuppression... 
GLIOMAS | THERAPY | ANTI-PD-1 | ONCOLOGY | CANCER | PD-1 BLOCKADE
Journal Article
European Journal of Cancer, ISSN 0959-8049, 03/2019, Volume 110, pp. 8 - 10
Journal Article
Cancer Research, ISSN 0008-5472, 10/2014, Volume 74, Issue 19, pp. 5458 - 5468
Radiotherapy is a major part in the treatment of most common cancers, but many patients experience local recurrence with metastatic disease. In evaluating... 
CELLS | RESPONSES | ANTICANCER CHEMOTHERAPY | MELANOMA | ANTI-PD-1 ANTIBODY | ONCOLOGY | SAFETY | TUMOR | LYMPHOMA | CANCER | RADIATION-THERAPY | Animals | Antigens, Neoplasm - immunology | Dose Fractionation | Immunologic Memory | Mice | CD8-Positive T-Lymphocytes - immunology | B7-H1 Antigen - immunology | Antibodies, Monoclonal - immunology | Disease Models, Animal
Journal Article
Annals of Oncology, ISSN 0923-7534, 03/2019, Volume 30, Issue 3, pp. 405 - 411
Abstract Background Standard first-line treatment of metastatic triple-negative breast cancer (mTNBC) is chemotherapy. However, outcomes are poor, and new... 
pembrolizumab | triple-negative breast neoplasms | ONCOLOGY | anti-PD-1 | PD-L1 EXPRESSION | immunotherapy
Journal Article
Journal of Hepatology, ISSN 0168-8278, 06/2018, Volume 68, Issue 6, pp. 1181 - 1190
Immunotherapy for metastatic cancer can be complicated by the onset of hepatic immune-related adverse events (IRAEs). This study compared hepatic IRAEs... 
Immune checkpoints inhibitors | Immunotherapy | Immune-related adverse events | COMBINED NIVOLUMAB | TOXICITIES | PEMBROLIZUMAB | HEPATITIS | ADVANCED MELANOMA | ANTI-PD-1 | BLOCKADE | GASTROENTEROLOGY & HEPATOLOGY | ADVERSE EVENTS | IPILIMUMAB | PHASE-2 TRIAL
Journal Article
FRONTIERS IN ONCOLOGY, ISSN 2234-943X, 01/2015, Volume 4, p. 385
Checkpoint blocking antibodies targeting regulatory molecules on T cells such as CTLA-4 and PD-1 have reinvigorated the field of cancer immunotherapy.These... 
RESPONSES | MELANOMA | nivolumab | ONCOLOGY | SAFETY | CLTA-4 | ipilimumab | immunotherapy | ANTIBODY | ANTI-PD-1 | PD-1 | T-CELLS | Immunotherapy | Nivolumab
Journal Article
Cancer Epidemiology Biomarkers and Prevention, ISSN 1055-9965, 12/2014, Volume 23, Issue 12, pp. 2965 - 2970
Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell activation facilitating disease progression. Preliminary clinical trials... 
SURVIVAL | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | B7-H1 PD-L1 | MELANOMA | ONCOLOGY | SAFETY | POOR-PROGNOSIS | ANTI-PD-1 | HUMAN BREAST-CANCER | EXPRESSION | CARCINOMA | LYMPHOCYTES | Prognosis | Neoplasms - genetics | Humans | Female | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Disease Progression
Journal Article
Annals of Oncology, ISSN 0923-7534, 08/2017, Volume 28, Issue 8, pp. 1988 - 1995
Background: Surrogate biomarkers of efficacy are needed for anti-PD1/PD-L1 therapy, given the existence of delayed responses and pseudo-progressions. We... 
Anti-PD-1 mAbs | Serum biomarkers | NSCLC | IL-8 | Anti-CTLA-4 mAbs | Melanoma | CRITERIA | anti-CTLA-4 mAbs | THERAPY | ONCOLOGY | SAFETY | serum biomarkers | melanoma | anti-PD-1 mAbs | NIVOLUMAB | EXPRESSION | Original articles
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 10, pp. 1020 - 1030
Journal Article